Donald Ammerman, MD
Psychiatry · Danbury, CTNPI 1316032295
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,376,341 of the $1,516,751 with a category attached, or 90.7%. 20 manufacturers reported payments, led by AbbVie at 52.5% of the total. 2025 is the largest year on record at $411,966, 4.9 times the $84,507 reported in 2019. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,083 payments — averaging $728.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$796K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$521K
- Neurocrine Biosciences, Inc.$165K
- Vanda Pharmaceuticals Inc.$34K
- E.r. Squibb & Sons, L.L.C.$309
- Teva Pharmaceuticals USA, Inc.$140
- plus $785 from 14 others
What the payments were for
- Consulting fees$21,6691%
- Speaking & faculty fees$1,376,34191%
- Travel & lodging$74,2235%
- Food & beverage$44,4793%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,212 | $795,699 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 564 | $520,937 |
| Neurocrine Biosciences, Inc. | 189 | $165,271 |
| Vanda Pharmaceuticals Inc. | 61 | $33,609 |
| E.r. Squibb & Sons, L.L.C. | 15 | $309 |
| Teva Pharmaceuticals USA, Inc. | 6 | $140 |
| Supernus Pharmaceuticals, Inc. | 4 | $128 |
| Otsuka America Pharmaceutical, Inc. | 6 | $124 |
| Johnson & Johnson | 4 | $86 |
| Sunovion Pharmaceuticals Inc. | 7 | $73 |
| Neuronetics, Inc. | 1 | $73 |
| Alkermes, Inc. | 3 | $56 |
| Avanir Pharmaceuticals, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Tempus AI, Inc | 2 | $40 |
| Lundbeck LLC | 1 | $33 |
| Arbor Pharmaceuticals, Inc. | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Tris Pharma Inc | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,516,751 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 36 | $56,784 |
| CaplytaLumateperone Tosylate | 15 | $26,084 |
| Bupropion XlBupropion Hcl | 58 | $2,116 |
| Divalproex Sodium | 39 | $1,241 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 31 | $1,194 |
| Trazodone Hcl | 57 | $991 |
| Quetiapine Fumarate | 53 | $930 |
| Olanzapine | 27 | $914 |
| Divalproex Sodium ErDivalproex Sodium | 20 | $888 |
| Fluoxetine Hcl | 43 | $837 |
| Duloxetine Hcl | 34 | $602 |
| Mirtazapine | 25 | $601 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $599 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $591 |
| Prazosin Hcl | 31 | $582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $795,699 | $56,78436 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $520,937 | $26,08415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Danbury
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Ghazi AsaadDanbury$29K
- Joseph WilliamsDanbury$28K
- Jeffrey SatinoverDanbury$16K
- Vladimir CoricNew Haven$133.7M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.